Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced participation in the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced participation in the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. CEO Jeff Goater and CMO Robert Ross, M.D., will discuss key programs, including SRF617 targeting CD39 and SRF388 targeting IL-27. Additionally, they will highlight the preclinical pipeline featuring SRF813, which targets CD112R (PVRIG). Surface Oncology focuses on developing innovative antibody therapies aimed at enhancing anti-tumor responses.
Details
News Market Reaction – SURF
The recorded move for SURF in the trading session of this news was +4.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, where they will discuss Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging preclinical pipeline, highlighted by SRF813 (targeting CD112R, also known as PVRIG).
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698
Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.